The addition of a covalent warhead permitted this to act at G12C, eliciting anti-proliferative effects in the NCI-H358 KRAS G12C mutant lung cancer cell line that were comparable to that of sotorasib (26 nM potency) (Bröker et al., 2022). This evidence concerns the gene KRAS and lung cancer.